Wolters Kluwer Enhances Formulary Monograph Service and Pharmacogenomics Content in Lexicomp
The Health division of Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, is continuing its commitment to providing user-friendly access to timely, relevant drug information by enhancing valuable special features in its Lexicomp® Online electronic drug reference solution. This includes upgrading the interface of the Formulary Monograph Service module and introducing summary pharmacogenomics monographs for easier, point-of-care clinical use.
Formulary Monograph Service, available as an optional add-on module to Lexicomp Online, provides access to information on newly released and investigational drugs to assist with Pharmacy & Therapeutics reviews, drug use evaluations, and other formulary decisions. Its new, convenient interface looks and feels like the rest of Lexicomp Online, with more user-friendly navigation to provide a better overall user experience within the Lexicomp workflow.
Lexicomp has long been at the forefront of providing pharmacogenomics content and helping professionals incorporate this evolving field of study into clinical practice. New summary pharmacogenomics monographs facilitate quicker access to actionable content, focusing on a single drug or drug class, management considerations, and quality of evidence. Summary monographs also link to traditional Lexicomp in-depth pharmacogenomics monographs, which delve deeper into information on the relevant gene for research purposes.
“Providing efficient access to drug information designed for use in clinical practice has long been a hallmark of Lexicomp medication safety resources,” said Denise Basow, MD, President & CEO of Clinical Effectiveness at Wolters Kluwer. “Our ongoing development efforts and enhancements are driven by the needs of our clinician users to make it as easy as possible for them to reach the crucial information they seek to help them make smart decisions and provide better care.”
About Wolters Kluwer
Wolters Kluwer N.V. (AEX:WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
Wolters Kluwer | Clinical Effectiveness
Meagan McCord, 330-650-6506
Manager, Marketing Communications, Clinical Drug Information